Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Biogen Inc Market Cap
From what 32 stock analysts predict, the share price for Biogen Inc (BIIB) might increase by 44.51% in the next year. This is based on a 12-month average estimation for BIIB. Price targets go from $190 to $342. The majority of stock analysts believe BIIB is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Biogen Inc has a total of 32 Wall St Analyst ratings. There are 21 buy ratings, 11 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Biogen Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of BIIB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Brian Abrahams RBC Capital | Outperform | $269 | Maintains | Oct 4, 2024 |
| Colin Bristow UBS | Neutral | $202 | Maintains | Oct 3, 2024 |
| Ami Fadia Needham | Buy | $285 | Reiterates | Sep 24, 2024 |
| Laura Chico Wedbush | Neutral | $205 | Maintains | Sep 23, 2024 |
| Brian Abrahams RBC Capital | Outperform | $292 | Reiterates | Sep 19, 2024 |
| Eric Schmidt Cantor Fitzgerald | Overweight | $292 | Reiterates | Sep 9, 2024 |
| Ami Fadia Needham | Buy | $285 | Reiterates | Sep 4, 2024 |
| Ami Fadia Needham | Buy | $285 | Reiterates | Aug 19, 2024 |
| Salim Syed Mizuho | Outperform | $251 | Maintains | Aug 6, 2024 |
| Ami Fadia Needham | Buy | $285 | Maintains | Aug 5, 2024 |
| Srikripa Devarakonda Truist Securities | Buy | $302 | Reiterates | Aug 5, 2024 |
| Brian Abrahams RBC Capital | Outperform | $292 | Maintains | Aug 2, 2024 |
| Carter Gould Barclays | Equal-Weight | $190 | Maintains | Aug 2, 2024 |
| Laura Chico Wedbush | Neutral | $210 | Maintains | Aug 2, 2024 |
| Mohit Bansal Wells Fargo | Equal-Weight | $225 | Maintains | Aug 2, 2024 |
| George Farmer Scotiabank | Sector Outperform | $244 | Maintains | Aug 2, 2024 |
| Ami Fadia Needham | Buy | $288 | Reiterates | Aug 1, 2024 |
| Brian Skorney Baird | Outperform | $294 | Maintains | Jul 29, 2024 |
| Ami Fadia Needham | Buy | $294 | Reiterates | Jul 26, 2024 |
| Christopher Raymond Piper Sandler | Overweight | $313 | Maintains | Jul 12, 2024 |
When did it IPO
1991
Staff Count
7,570
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - General
CEO
Mr. Christopher A. Viehbacher
Market Cap
$27.05B
In 2023, BIIB generated $9.84B in revenue, which was a decrease of -3.32% from the previous year. This can be seen as a signal that BIIB's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sun, 06 Oct 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - AI is enhancing drug discovery in biotech and pharma, speeding up processes and improving success rates, indicating potential contrarian buying opportunities in the sector.
Why It Matters - AI's impact on drug discovery enhances efficiency and success rates in biotech, potentially leading to lucrative investments and faster returns in the sector.
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - The phase III PHOENYCS GO study of dapirolizumab pegol, developed by BIIB and UCB for systemic lupus erythematosus, has successfully met its primary endpoint.
Why It Matters - The successful phase III study for dapirolizumab pegol enhances BIIB and UCB's market potential in autoimmune therapies, likely boosting their stock values and investor confidence.
Fri, 27 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Sage Therapeutics has terminated its collaboration with Biogen for SAGE-324, a treatment for essential tremor.
Why It Matters - The discontinuation signals potential setbacks for SAGE-324's development, impacting Sage Therapeutics' growth prospects and Biogen's pipeline, which may affect stock performance and investor sentiment.
Tue, 24 Sep 2024
Sentiment - POSITIVE
Source - Reuters
Summary - Biogen and UCB announced that their experimental lupus treatment successfully met the primary endpoint in a late-stage trial, despite previous failure in a mid-stage study.
Why It Matters - Biogen's lupus treatment success in late-stage trials can boost investor confidence, potentially leading to increased stock value and market interest, despite previous setbacks.
Tue, 24 Sep 2024
Sentiment - POSITIVE
Source - Market Watch
Summary - Biogen's stock increased by 2% after positive late-stage trial results were announced in collaboration with Belgian partner UCB.
Why It Matters - Biogen's stock rise indicates investor confidence following positive trial results, which can lead to potential revenue growth and increased market valuation.
Tue, 24 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - UCB and Biogen reported positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement over placebo after 48 weeks.
Why It Matters - Positive Phase 3 results for dapirolizumab pegol suggest potential market success for UCB and Biogen, impacting stock valuations and investor sentiment in the biopharmaceutical sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
